Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics


Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP)

Today's Latest Price: $77.26 USD

0.89 (-1.14%)

Updated Oct 28 4:00pm

Add HZNP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

HZNP Stock Summary

  • HZNP has a higher market value than 88.79% of US stocks; more precisely, its current market capitalization is $15,953,192,867.
  • Price to trailing twelve month operating cash flow for HZNP is currently 50.5, higher than 92.96% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 10.51, Horizon Therapeutics Public Ltd Co has a higher such ratio than 86.8% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Horizon Therapeutics Public Ltd Co, a group of peers worth examining would be EXAS, AYX, NTRA, BL, and AKAM.
  • Visit HZNP's SEC page to see the company's official filings. To visit the company's web site, go to www.horizontherapeutics.com.

HZNP Stock Price Chart Interactive Chart >

Price chart for HZNP

HZNP Price/Volume Stats

Current price $77.26 52-week high $86.67
Prev. close $78.15 52-week low $23.81
Day low $74.79 Volume 1,722,300
Day high $77.91 Avg. volume 2,210,425
50-day MA $76.90 Dividend yield N/A
200-day MA $52.25 Market Cap 15.95B

Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio


Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.

HZNP Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$77.26$45.26 -41%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Horizon Therapeutics Public Ltd Co. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 34th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 41.17%. In terms of the factors that were most noteworthy in this DCF analysis for HZNP, they are:

  • The compound growth rate in the free cash flow of Horizon Therapeutics Public Ltd Co over the past 5.44 years is 0.45%; that's better than 74.17% of cash flow producing equities in the Healthcare sector, where it is classified.
  • The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately merely 18.78% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 115 -- greater than 97.77% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-43%
1%-42%
2%-41%
3%-41%
4%-40%
5%-40%

EDAP, MD, CMD, OSMT, and CRL can be thought of as valuation peers to HZNP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


HZNP Latest News Stream


Event/Time News Detail
Loading, please wait...

HZNP Latest Social Stream


Loading social stream, please wait...

View Full HZNP Social Stream

Latest HZNP News From Around the Web

Below are the latest news stories about Horizon Therapeutics Public Ltd Co that investors may wish to consider to help them evaluate HZNP as an investment opportunity.

Horizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of Adoption

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) was named as a 2020 Angels in Adoption® Honoree for the company’s outstanding advocacy for adoption of children living with rare diseases. The Congressional Coalition on Adoption Institute (CCAI), which coordinates the Angels in Adoption® Program, honored Horizon at its virtual gala on Sept. 30, 2020. The company was nominated by U.S. Senator Tammy Duckworth (D-IL). Horizon was recognized for its innovative #RAREis Adoption Fund p

Business Wire | October 1, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the complete dataset on the primary endpoint from its Methotrexate to Increase Response Rates in Patients With Uncontrolled GOut Receiving KRYSTEXXA (MIRROR) open-label trial in the Journal of Rheumatology [https://doi.org/10.3899/jrheum.200460]. Horizon’s MIRROR clinical program includes the completed multi-center, open-label trial as well as an ongoing randomized controlled trial (RCT). The tri

Business Wire | September 16, 2020

Horizon Therapeutics plc Named to the 2020 PEOPLE “50 Companies That Care” List

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of PEOPLE’s “50 Companies That Care” for 2020. The 2020 “50 Companies That Care” list spotlights 50 U.S. companies with 1,000 or more employees and their response to taking care of their employees, their communities and the world during the COVID-19 crisis. The list will be featured in the Sept. 14, 2020 print issue of PEOPLE. “It is a special honor to be recognized by PEOPLE and Great Pl

Business Wire | September 2, 2020

Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the closing of its underwritten public offering of 13,570,000 of its ordinary shares at a price to the public of $71.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,770,000 additional ordinary shares. The net proceeds to the Company from this offering are expected to be approximately $919.3 million, after deducting underwriting discounts and other estimated o

Business Wire | August 11, 2020

Read More 'HZNP' Stories Here

HZNP Price Returns

1-mo -1.15%
3-mo 26.26%
6-mo 116.90%
1-year 165.22%
3-year 462.71%
5-year 391.48%
YTD 113.43%
2019 85.26%
2018 33.84%
2017 -9.77%
2016 -25.33%
2015 68.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9473 seconds.